SG44523A1 - Quinoline derivatives - Google Patents

Quinoline derivatives

Info

Publication number
SG44523A1
SG44523A1 SG1996001518A SG1996001518A SG44523A1 SG 44523 A1 SG44523 A1 SG 44523A1 SG 1996001518 A SG1996001518 A SG 1996001518A SG 1996001518 A SG1996001518 A SG 1996001518A SG 44523 A1 SG44523 A1 SG 44523A1
Authority
SG
Singapore
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
SG1996001518A
Other languages
English (en)
Inventor
Hiroshi Hasegawa
Kazuo Isomae
Takeshi Kotsugai
Noriaki Shiori
Kumiko Sekine
Naokata Taido
Susumu Sato
Tadayuki Kurraishi
Original Assignee
Ss Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ss Pharmaceutical Co filed Critical Ss Pharmaceutical Co
Publication of SG44523A1 publication Critical patent/SG44523A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG1996001518A 1990-10-19 1991-10-15 Quinoline derivatives SG44523A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28109490 1990-10-19
JP28109390 1990-10-19

Publications (1)

Publication Number Publication Date
SG44523A1 true SG44523A1 (en) 1997-12-19

Family

ID=26554052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001518A SG44523A1 (en) 1990-10-19 1991-10-15 Quinoline derivatives

Country Status (8)

Country Link
US (2) US5190951A (fr)
EP (2) EP0987262A1 (fr)
KR (1) KR100206200B1 (fr)
CA (1) CA2053640C (fr)
DE (1) DE69132519T2 (fr)
ES (1) ES2156853T3 (fr)
HK (1) HK1011351A1 (fr)
SG (1) SG44523A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
EP0833638B1 (fr) * 1995-06-15 2001-11-21 PHARMACIA & UPJOHN COMPANY UTILISATION D'IMIDAZO(1,5-a)QUINOLONES COMME AGENTS NEUROPROTECTEURS
EP1086102A1 (fr) * 1998-06-10 2001-03-28 Arena Pharmaceuticals, Inc. Activateurs d'acetylcholine
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
ES2297217T3 (es) 2002-06-19 2008-05-01 Janssen Pharmaceutica Nv Derivados sustituidos de 2,4-dihidro-pirrolo(3,4-b)quinolin-9-ona utilizados como inhibidores de fosfodiesterasa.
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
BRPI0620126A2 (pt) * 2005-12-20 2011-11-01 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, método para modular a atividade de um receptor de gabaa, e, método sintético para fabricar um composto
AR067027A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
TW200911760A (en) * 2007-06-19 2009-03-16 Astrazeneca Ab Compounds and uses thereof
EP2533645B1 (fr) * 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
CA2818025A1 (fr) 2010-11-15 2012-05-24 Agenebio, Inc. Derives de pyridazine, compositions et methodes de traitement d'une deficience cognitive
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
CN102875602B (zh) * 2012-10-25 2015-05-20 江苏神龙药业有限公司 一种米诺膦酸水合物的制备方法
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
WO2016205739A1 (fr) 2015-06-19 2016-12-22 Belew Mekonnen Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN112608326B (zh) * 2021-01-22 2021-10-01 河南大学 呋喃并[2,3-b]喹啉-3,4（2H,9H)-二酮衍生物、其制备方法及应用
CN114989180B (zh) * 2022-05-26 2024-06-04 广东海洋大学 杨叶肖槿内生真菌来源的化合物及其制备方法与应用
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2507076B2 (ja) * 1989-08-11 1996-06-12 株式会社クボタ カ―ド式自動販売機
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives

Also Published As

Publication number Publication date
HK1011351A1 (en) 1999-07-09
DE69132519D1 (de) 2001-03-01
EP0987262A1 (fr) 2000-03-22
US5190951A (en) 1993-03-02
KR920008024A (ko) 1992-05-27
US5300517A (en) 1994-04-05
KR100206200B1 (ko) 1999-07-01
ES2156853T3 (es) 2001-08-01
EP0481429A3 (en) 1992-08-19
EP0481429B1 (fr) 2001-01-24
EP0481429A2 (fr) 1992-04-22
DE69132519T2 (de) 2001-06-13
CA2053640C (fr) 2001-12-25
CA2053640A1 (fr) 1992-04-20

Similar Documents

Publication Publication Date Title
GB9108547D0 (en) Quinoline derivatives
EP0481429A3 (en) Quinoline derivatives
EP0440950A3 (en) Halogenallyl-azolyl derivatives
HU912356D0 (en) Rapacmycine derivatives
EP0470466A3 (en) Halogenalkyl-azolyl derivatives
IL96819A0 (en) Azaoxindole derivatives
LTIP848A (en) Hiv-inhibiting benzene-acetamide derivatives
IL99576A0 (en) Triazacyclohexane derivatives
ZA915595B (en) Carbostyril derivatives
EP0485984A3 (en) Diarylmethoxypiperidine derivatives
IL101627A0 (en) 4-aryl-3-(heteroarylureido)quinoline derivatives
OA09670A (en) Carbo-nucleoside derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
GB9126438D0 (en) New quinoline derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
AP9100308A0 (en) Carboxymethylcyclopropane derivatives
IE901869L (en) Quinoline derivatives
GB2249094B (en) Hetero-imidazodiazepine derivatives
IE900817L (en) Tetrahydroquinoline derivatives
GB9006772D0 (en) 4-piperidinyl-ergoline derivatives
EG19474A (en) Nitroenamine derivatives
EG19362A (en) Azoaxindole derivatives
GB9201427D0 (en) Quinoline derivatives
ZA901927B (en) Quinoline derivatives
IE892913L (en) Quinoline derivatives